Clinical trials: Advanced Hepatocellular Carcinoma, open to volunteers
Hepatocellular Carcinoma (HCC)
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
- Trial name
- NCT06860490
- Testing
- Sintilimab, Bevacizumab Biosimilar, HAIC
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC)
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii.
- Trial name
- NCT07075120
- Testing
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
Advanced Hepatocellular Carcinoma, Cirrhosis
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07042919
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Devalingam Mahalingam
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Advanced Hepatocellular Carcinoma
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of Intravenous CD-801 treatment in subjects with advanced hepatocellular carcinoma(HCC).
- Trial name
- NCT06418659
- Testing
- CD-801
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Hepatocellular Carcinoma, Hepatic Chemotherapy
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
This study intends to compare the efficacy of transcatheter arterial chemical embolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) for patients with intermediate-advanced huge hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
- Trial name
- NCT06641713
- Testing
- TACE, HAIC
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
- Trial name
- NCT05985798
- Testing
- Sin-Bev-TACE, Len-TACE
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
This prospective, single-arm study was aimed to evaluate the efficacy of recombinant human adenovirus type 5 injection combined with tislelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06253598
- Testing
- Recombinant Human Adenovirus Type 5, Lenvatinib, Tislelizumab
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
The goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult…
- Trial name
- NCT06680258
- Testing
- TPST-1120, Atezolizumab, Bevacizumab
- Volunteers
- 740 people
- Sponsor
- Tempest Therapeutics
Cachexia, Digestive System Cancer
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
- Conditions
- Cachexia, Digestive System Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06940102
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, TKI-Based Therapy
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in…
- Trial name
- NCT05323201
- Testing
- fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University